EPIK-P2NCT04589650
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 40 versions: 38 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Minor Enrollment increased: 206 → 236 participants Show 5 more changesShow less
- Eligibility criteria expanded, about 33 words
- Secondary endpoints: details revised at 17 of 22 entries
- Study sites revised (36)
- Publications: details revised at 2 of 2 entries
- Study description expanded, about 2 words
- Minor Site details revised at 3 of 36 sitesv39
- Minor Site details revised at 1 of 36 sitesv38
- Minor Enrollment target: 203 to 206
- Study completion date: Jan 17, 2031 to Jan 9, 2031
- Site details revised at 2 of 36 sites
- Minor Enrollment target: 200 to 203
- Site details revised at 1 of 36 sites
Show 32 earlier versionsHide 32 earlier versions
- Minor Enrollment target: 205 to 200
- Study completion date: Feb 28, 2031 to Jan 17, 2031
- Study description expanded, about 557 words
- Study sites revised (36)
- Minor Study sites: 35 to 36v33
- Minor Study sites: 36 to 35
- Study completion date: Feb 21, 2031 to Feb 28, 2031
- Minor Study completion date: Feb 14, 2031 to Feb 21, 2031
- Site details revised at 1 of 36 sites
- Minor Enrollment target: 188 to 205
- Site details revised at 5 of 36 sites
Notable Results first posted: Feb 10, 2025v29 Show 7 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 205 to confirmed 188
- Study sites: 39 to 36
- Study completion date: Apr 28, 2031 to Feb 14, 2031
- Secondary endpoints revised (22)
- Primary endpoint revised
- Study description shortened, about 3 words
- Minor Eligibility criteria expanded, about 240 words
- Secondary endpoints revised (22)
- Study description expanded, about 52 words
- Study sites revised (39)
- Minor Site details revised at 2 of 39 sitesv27
- Minor Enrollment target: 189 to 205
- Study completion date: Mar 27, 2031 to Apr 28, 2031
- Site details revised at 1 of 39 sites
- Minor Study sites revised (39)v25
- Minor Study completion date: Mar 11, 2031 to Mar 27, 2031
- Study sites revised (39)
- Minor Primary completion date changed from estimate of Jun 7, 2030 to Mar 20, 2024
- Study completion date: Jun 7, 2030 to Mar 11, 2031
- Study sites revised (39)
- Minor Site details revised at 3 of 39 sitesv22
- Minor Study sites revised (39)v21
- Minor Study description revised
- Study sites revised (39)
- Notable Primary and study completion dates pushed to Jun 7, 2030v19
- Minor Study sites revised (39)v18
- Minor Primary completion date: Jun 8, 2023 to Sep 20, 2023v17
- Minor Eligibility criteria expanded, about 75 words
- Site details revised at 3 of 39 sites
Notable Primary endpoint revisedv15 Show 8 more changesShow less
- Enrollment target: 174 to 189
- Study sites: 33 to 39
- Primary completion date: Mar 27, 2023 to Jun 8, 2023
- Study completion date: Dec 26, 2029 to Feb 25, 2030
- Secondary endpoints: 20 to 22
- Study description expanded, about 27 words
- Study arms: 6 to 7
- Eligibility criteria expanded, about 2 words
- Minor Study sites: 31 to 33v13
- Minor Site contacts updated at 1 of 31 sitesv12
- Minor Study sites: 30 to 31v11
- Minor Enrollment target: 150 to 174
- Study sites: 26 to 30
Minor Study sites: 25 to 26v9 Show 4 more changesShow less
- Eligibility criteria expanded, about 135 words
- Secondary endpoints: 19 to 20
- Study description expanded, about 58 words
- Study arms: 5 to 6
- Minor Study sites: 21 to 25v8
- Minor Study sites: 15 to 21v7
- Minor Study sites: 9 to 15v6
- Minor Study sites: 4 to 9v5
- Minor Study sites: 2 to 4v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Start date changed from estimate of Mar 31, 2021 to Apr 19, 2021
- Notable Start date: Feb 2, 2021 to Mar 31, 2021
- Primary completion date: Jan 27, 2023 to Mar 27, 2023
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (22)
Show 17 moreShow less
Arms and interventions
During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive alpelisib (125 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive placebo. After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
During double-blind randomized study period (from baseline up to Week 16, pediatric participants (6 to 17 years old) will be randomized to receive alpelisib (50 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
During double-blind randomized study period (from baseline up to Week 16), pediatric participants (6 to 17 years old) will be randomized to receive Placebo. After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
Pediatric participants (0 to 5 years old) will receive alpelisib granules formulation with an age-dependent starting dose (\<1 month: 20 mg every other day; 1 to \<6 months: 20 mg daily; 6 to \<2 years: 40 mg daily; 2 to \<6 years: 50 mg daily).
Pediatric participants (2 to 5 years old) will receive 50 mg of alpelisib film-coated tablets (FCT) once daily in an open-label setting.
Pediatric participants (6 to 17 year old) will receive 125 mg alpelisib film-coated (FCT) once daily, in an open-label setting.
Drugs: Alpelisib, Placebo
Sites
36 sites in 12 countries
United States 11, Germany 5, France 4, United Kingdom 3, Canada 2, China 2, Italy 2, Spain 2, Switzerland 2, Hong Kong 1, Netherlands 1, Norway 1